Form 4 for MNKD MANNKIND CORP
Accepted 2026-05-22 20:48:42 ET · period of report 2026-05-20 · accession 0001193125-26-237428 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-22 20:48 | 2026-05-20 | MNKD | Marasco Dominic | Pres, Endocrine Business Unit | A - Grant | $2.95 | +8,474 | 344.2K | +3% | +$25.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.01 Par Value | 2026-05-20 | A | A | 8,474 | $2.95 | 344,246 | D | — | — | (F1) The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 29, 2018. The purchase was approved by the Company's Board of Directors on May 20, 2026. (F2) Includes 2,343 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2025. |